Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Drug Resistance, Bacterial.
Connection Strength

3.874
  1. Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: In vitro model studies with linezolid and gentamicin. Int J Antimicrob Agents. 2018 Dec; 52(6):854-860.
    View in: PubMed
    Score: 0.428
  2. Burden of antimicrobial resistance in an era of decreasing susceptibility. Expert Rev Anti Infect Ther. 2017 07; 15(7):663-676.
    View in: PubMed
    Score: 0.392
  3. Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin. J Chemother. 2017 Aug; 29(4):220-226.
    View in: PubMed
    Score: 0.375
  4. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment. Int J Antimicrob Agents. 2015 Sep; 46(3):313-8.
    View in: PubMed
    Score: 0.344
  5. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. Int J Antimicrob Agents. 2014 Oct; 44(4):301-5.
    View in: PubMed
    Score: 0.321
  6. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J Antimicrob Chemother. 2013 Apr; 68(4):881-7.
    View in: PubMed
    Score: 0.286
  7. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother. 2008 Jun; 52(6):1924-8.
    View in: PubMed
    Score: 0.207
  8. Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. J Antimicrob Chemother. 2008 Mar; 61(3):629-35.
    View in: PubMed
    Score: 0.205
  9. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother. 2003 Oct; 52(4):616-22.
    View in: PubMed
    Score: 0.151
  10. Anti-mutant efficacy of antibiotic combinations: in vitro model studies with linezolid and daptomycin. J Antimicrob Chemother. 2021 06 18; 76(7):1832-1839.
    View in: PubMed
    Score: 0.129
  11. Resistance studies with Streptococcus pneumoniae using an in vitro dynamic model: amoxicillin versus azithromycin at clinical exposures. J Chemother. 2019 Sep; 31(5):252-260.
    View in: PubMed
    Score: 0.113
  12. Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid. J Antibiot (Tokyo). 2018 05; 71(5):514-521.
    View in: PubMed
    Score: 0.102
  13. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model. J Antimicrob Chemother. 2017 Nov 01; 72(11):3100-3107.
    View in: PubMed
    Score: 0.101
  14. Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically? J Chemother. 2017 Dec; 29(6):351-357.
    View in: PubMed
    Score: 0.098
  15. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. Antimicrob Agents Chemother. 2015 Dec 07; 60(3):1208-15.
    View in: PubMed
    Score: 0.088
  16. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration. J Antimicrob Chemother. 2016 Mar; 71(3):678-84.
    View in: PubMed
    Score: 0.088
  17. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother. 2012 Mar; 56(3):1223-8.
    View in: PubMed
    Score: 0.067
  18. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J Antimicrob Chemother. 2009 Oct; 64(4):815-20.
    View in: PubMed
    Score: 0.057
  19. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int J Antimicrob Agents. 2008 Dec; 32(6):488-93.
    View in: PubMed
    Score: 0.053
  20. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother. 2006 Dec; 58(6):1185-92.
    View in: PubMed
    Score: 0.047
  21. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 2005 May; 25(5):409-13.
    View in: PubMed
    Score: 0.042
  22. Fluoroquinolone prophylaxis in patients with neutropenia. Clin Infect Dis. 2005 Apr 15; 40(8):1094-5.
    View in: PubMed
    Score: 0.042
  23. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004 Jul; 54(1):178-86.
    View in: PubMed
    Score: 0.040
  24. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents. 2004 May; 23(5):451-6.
    View in: PubMed
    Score: 0.039
  25. Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitro dynamic model. J Chemother. 2018 Oct - Dec; 30(6-8):364-370.
    View in: PubMed
    Score: 0.027
  26. In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients. Eur J Clin Microbiol Infect Dis. 2006 Aug; 25(8):537-40.
    View in: PubMed
    Score: 0.012
  27. Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations. Int J Antimicrob Agents. 2005 Sep; 26(3):197-204.
    View in: PubMed
    Score: 0.011
  28. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Sep; 20(3):201-5.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.